David Matheson discusses the patient perspective on radiographic progression-free survival as a clinical trial endpoint. Dr. Matheson argues that imaging-based progression is more ...
Tyler Seibert outlines his approach to radiation therapy for the primary tumor in metastatic hormone-sensitive prostate cancer. He summarizes three randomized trials that consiste ...
(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to a session on non-beta emitter PSMA radioligand therapy. Dr. David ...
(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, between June 21 st and 24 th, 2025, was host to the Barry Siegel Award Lecture ...
(UroToday.com) Prof Vittorio Canale presented his experience implementing and disseminating an ERAS program at his organization. Basic tenets need to be reinforced and audited. ERAS in Urology: A ...
Matthew Cooperberg speaks with Martin Gleave about GUNS, a neoadjuvant adaptive umbrella trial for men with high-volume, high-grade prostate cancer. Now at 280 patients enrolled, GUNS sequences needle ...
(UroToday.com) The 2025 APCCC Diagnostics annual meeting featured a session on how to stage and estimate risk for prostate cancer and a presentation by Dr. Derya Tilki discussing which patients need ...
Alicia Morgans: I am going to be talking about incorporating PSMA PETs into registration trials with an example of a study that is relying on a PSMA PET endpoint as the primary endpoint in the study.
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions for patients with prostate cancer across the disease spectrum. The Guidelines sections included in this article ...
The Kurt extraperitoneal ligamentopexy: A new surgical method with uterine preservation for pelvic organ prolapse, "Beyond the Abstract," by Sefa Kurt and Mehmet Tunc Canda ...
Chronic prostatitis/chronic pelvic pain syndrome: Interplay of inflammatory mediators, "Beyond the Abstract," by Dan Lundh, Hans Hedelin, and Dennis Larsson ...
ASCO GU 2020 Prostate Cancer Randomized phase 2 study of sipuleucel-T (Sip-T) with or without radium-233 (Ra-223) in men with bone metastatic castration-resistant prostate cancer - Poster ASCO GU 2020 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results